keyword
MENU ▼
Read by QxMD icon Read
search

Lurasidone

keyword
https://www.readbyqxmd.com/read/28225748/case-series-reports-on-lurasidone-associated-mania
#1
Louis A Doan, Steven R Williams, Alexandra Takayesu, Brett Lu
No abstract text is available yet for this article.
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28185899/lurasidone-versus-treatment-as-usual-for-cognitive-impairment-in-euthymic-patients-with-bipolar-i-disorder-a-randomised-open-label-pilot-study
#2
Lakshmi N Yatham, Sylvia Mackala, Jayasree Basivireddy, Sharon Ahn, Nazlin Walji, Chen Hu, Raymond W Lam, Ivan J Torres
BACKGROUND: Cognitive impairment is present in euthymic patients with bipolar disorder and correlates with impairments in everyday functioning. We aimed to examine the efficacy of lurasidone adjunctive therapy compared with treatment as usual (TAU) in improving cognition. METHODS: For this randomised, open-label, pilot study, we recruited patients aged 19-65 years with euthymic bipolar I disorder from the Mood Disorder Centre in UBC Hospital (Vancouver, Canada)...
February 6, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28168632/long-term-use-of-lurasidone-in-patients-with-bipolar-disorder-safety-and-effectiveness-over-2%C3%A2-years-of-treatment
#3
Andrei Pikalov, Joyce Tsai, Yongcai Mao, Robert Silva, Josephine Cucchiaro, Antony Loebel
BACKGROUND: Bipolar disorder is a chronic illness with a 2-year recurrence rate of approximately 50% among individuals receiving treatment in the community. The aim of this 18-month, open-label, continuation study was to evaluate the long-term safety and effectiveness of lurasidone in patients who initially presented with a major depressive episode associated with bipolar disorder, and who had completed at least 6 months of initial treatment with lurasidone. METHODS: Patients with bipolar I depression were enrolled in one of three 6-week, double-blind, placebo-controlled trials (monotherapy with lurasidone, 1 study; adjunctive therapy with lurasidone; and lithium or valproate, 2 studies)...
December 2017: International Journal of Bipolar Disorders
https://www.readbyqxmd.com/read/28141623/activating-and-sedating-adverse-effects-of-second-generation-antipsychotics-in-the-treatment-of-schizophrenia-and-major-depressive-disorder-absolute-risk-increase-and-number-needed-to-harm
#4
Leslie Citrome
PURPOSE/BACKGROUND: Activating and sedating adverse effects of antipsychotics can be obstacles to their use. METHODS/PROCEDURES: This study quantified the activating and sedating properties of first-line oral second-generation antipsychotics by examining the rates of adverse reactions as reported in product labeling for the indications of schizophrenia and adjunctive treatment of major depressive disorder. Additional data sources included regulatory documents, study synopses, and published study reports...
January 30, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28129315/lurasidone-and-mood-stabilizers-in-treatment-resistant-unipolar-depression-a-case-report-study
#5
Nicolas A Nuñez, Gabriella Gobbi
No abstract text is available yet for this article.
January 26, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28098496/real-world-adherence-assessment-of-lurasidone-and-other-oral-atypical-antipsychotics-among-patients-with-schizophrenia-an-administrative-claims-analysis
#6
Krithika Rajagopalan, Sally Wade, Nicole Meyer, Antony Loebel
OBJECTIVE: To compare adherence with lurasidone to other oral atypical antipsychotics among Medicaid and commercially insured patients with schizophrenia. RESEARCH DESIGN AND METHODS: Administrative claims of patients with schizophrenia treated with atypical antipsychotics (lurasidone, aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone) from October 2010 to September 2011 were identified from MarketScan Commercial and Medicaid Databases, and were classified by the first (index) antipsychotic...
February 6, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28043915/charge-assisted-bond-n-h-mediates-the-gelation-of-amorphous-lurasidone-hydrochloride-during-dissolution
#7
Shuai Qian, Shanshan Wang, Zhen Li, Xiaojie Wang, Di Ma, Shujun Liang, Yuan Gao, Jianjun Zhang, Yuanfeng Wei
Lurasidone hydrochloride (LH), the hydrochloride form of lurasidone with a charge-assisted bond N(+)H, is an atypical antipsychotropic agent for the treatment of schizophrenia. As a BCS class II drug, LH has a low oral bioavailability mainly due to its poor water solubility and low dissolution. In order to improve its solubility, amorphization of LH was performed and characterized. Unexpectedly, the dissolution rate of amorphous LH was much lower than that of crystalline LH. In addition, the amorphous LH powders quickly aggregated when contacting the dissolution media (water, 37°C), and formed a sticky gel adhering on the paddle...
December 30, 2016: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28008349/dosing-patterns-and-medication-adherence-in-bipolar-disorder-patients-treated-with-lurasidone-a-us-retrospective-claims-database-analysis
#8
Martha Sajatovic, Daisy Ng-Mak, Caitlyn T Solem, Fang-Ju Lin, Krithika Rajagopalan, Antony Loebel
BACKGROUND: The aim of this study was to describe dosing patterns and medication adherence among bipolar patients who initiated lurasidone in a real-world setting. METHODS: Adult bipolar patients who initiated lurasidone between 1 November 2010 and 31 December 2012 (index period) with 6-month pre- and post-index continuous enrollment were identified from the IMS RWD Adjudicated Claims US database. Patients were grouped by starting lurasidone daily dose: 20 mg (7...
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28004621/augmentation-of-phenelzine-with-aripiprazole-and-quetiapine-in-a-treatment-resistant-patient-with-psychotic-unipolar-depression-case-report-and-literature-review
#9
Jonathan M Meyer, Michael A Cummings, George Proctor
Irreversible monoamine oxidase inhibitor (MAOI) antidepressants have significant efficacy in treatment-resistant unipolar depression, but in some instances patients may not achieve remission. Among the adjunctive and augmentation strategies, certain second-generation antipsychotics (SGAs) have approval for inadequate responders to antidepressant therapy, including aripiprazole, brexpiprazole, and quetiapine, with lurasidone and the olanzapine/fluoxetine combination indicated for bipolar depression. Clinicians may eschew SGA options in part due to the limited literature on SGA-MAOI combinations, with only one published case involving aripiprazole, and none for olanzapine, lurasidone, or brexpiprazole...
December 22, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27939135/chronic-lurasidone-treatment-normalizes-gabaergic-marker-alterations-in-the-dorsal-hippocampus-of-mice-exposed-to-prenatal-immune-activation
#10
A Luoni, J Richetto, L Longo, M A Riva
Prenatal maternal infection represents a risk factor for the development of psychopathologic conditions later in life. Clinical evidence is also supported by animal models in which the vulnerability to develop a schizophrenic-like phenotype likely originates from inflammatory processes as early as in the womb. Prenatal immune challenge, for example, induces a variety of long-term behavioral alterations in mice, such as deficits in recognition and spatial working memory, perseverative behaviors and social impairments, which are relevant to different symptom clusters of schizophrenia...
February 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27935810/designing-and-analysing-clinical-trials-in-mental-health-an-evidence-synthesis-approach
#11
Simon Wandel, Satrajit Roychoudhury
OBJECTIVE: When planning a clinical study, evidence on the treatment effect is often available from previous studies. However, this evidence is mostly ignored for the analysis of the new study. This is unfortunate, since using it could lead to a smaller study without compromising power. We describe a design that addresses this issue. METHODS: We use a Bayesian meta-analytic model to incorporate the available evidence in the analysis of the new study. The shrinkage estimate for the new study integrates the evidence from the other studies...
November 2016: Evidence-based Mental Health
https://www.readbyqxmd.com/read/27833522/histamine-h3-receptors-and-its-antagonism-as-a-novel-mechanism-for-antipsychotic-effect-a-current-preclinical-clinical-perspective
#12
REVIEW
Danish Mahmood
Histamine H3 receptors are present as autoreceptors on histaminergic neurons and as heteroreceptors on nonhistaminergic neurones. They control the release and synthesis of histamine and several other key neurotransmitters in the brain. H3 antagonism may be a novel approach to develop a new class of antipsychotic medications given the gathering evidence reporting therapeutic efficacy in several central nervous system disorders. Several medications such as cariprazine, lurasidone, LY214002, bexarotene, rasagiline, raloxifene, BL-1020 and ITI-070 are being developed to treat the negative symptoms and cognitive impairments of schizophrenia...
October 2016: International Journal of Health Sciences
https://www.readbyqxmd.com/read/27722855/pharmacokinetics-and-pharmacodynamics-of-lurasidone-hydrochloride-a-second-generation-antipsychotic-a-systematic-review-of-the-published-literature
#13
REVIEW
William M Greenberg, Leslie Citrome
Lurasidone hydrochloride, a benzisothiazol derivative, is a second-generation (atypical) antipsychotic agent that has received regulatory approval for the treatment of schizophrenia in the US, Canada, the EU, Switzerland, and Australia, and also for bipolar depression in the US and Canada. In addition to its principal antagonist activity at dopamine D2 and serotonin 5-HT2A receptors, lurasidone has distinctive 5-HT7 antagonistic activity, and displays partial agonism at 5-HT1A receptors, as well as modest antagonism at noradrenergic α2A and α2C receptors...
October 8, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27629159/treatment-recommendations-for-dsm-5-defined-mixed-features
#14
Joshua D Rosenblat, Roger S McIntyre
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) mixed features specifier provides a less restrictive definition of mixed mood states, compared to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), including mood episodes that manifest with subthreshold symptoms of the opposite mood state. A limited number of studies have assessed the efficacy of treatments specifically for DSM-5-defined mixed features in mood disorders. As such, there is currently an inadequate amount of data to appropriately inform evidence-based treatment guidelines of DSM-5 defined mixed features...
September 15, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27563237/schizophrenia-relapse-patient-considerations-and-potential-role-of-lurasidone
#15
REVIEW
Leslie Citrome
When treating persons with schizophrenia, delaying time to relapse is a main goal. Antipsychotic medication has been the primary treatment approach, and there are a variety of different choices available. Lurasidone is a second-generation (atypical) antipsychotic agent that is approved for the treatment of schizophrenia and bipolar depression. Three long-term studies of lurasidone have examined time to relapse in persons with schizophrenia, including a classic placebo-controlled randomized withdrawal study and two 12-month active comparator studies (vs risperidone and vs quetiapine extended-release)...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27529375/efficacy-of-lurasidone-in-adults-aged-55-years-and-older-with-bipolar-depression-post-hoc-analysis-of-2-double-blind-placebo-controlled-studies
#16
Martha Sajatovic, Brent P Forester, Joyce Tsai, Hans Kroger, Andrei Pikalov, Josephine Cucchiaro, Antony Loebel
OBJECTIVE: The aim of this post hoc analysis was to evaluate the efficacy of lurasidone in patients aged 55 years and older with bipolar depression. METHODS: A post hoc analysis was performed on the older adult subgroup (n = 142) of outpatients meeting DSM-IV-TR criteria for bipolar I depression in 2 placebo-controlled, 6-week, randomized, double-blind studies conducted from 2009-2012: a monotherapy study comparing fixed flexible-dose ranges of lurasidone 20-60 mg/d or 80-120 mg/d with placebo and an adjunctive therapy study comparing flexible doses of lurasidone 20-120 mg/d with placebo adjunctive to either lithium or valproate...
October 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27518477/an-open-trial-of-lurasidone-as-an-acute-and-maintenance-adjunctive-treatment-for-outpatients-with-treatment-resistant-bipolar-disorder-response-to-letter-to-the-editors
#17
Charles B Schaffer, Linda C Schaffer, Thomas E Nordahl, Nicole M Stark, Caroline E Gohring
No abstract text is available yet for this article.
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27518474/comment-on-an-open-trial-of-lurasidone-as-an-acute-and-maintenance-adjunctive-treatment-for-outpatients-with-treatment-resistant-bipolar-disorder
#18
Ian Ross McGrane, Matej Stuhec
No abstract text is available yet for this article.
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27454547/lurasidone-dose-escalation-in-early-nonresponding-patients-with-schizophrenia-a-randomized-placebo-controlled-study
#19
Antony Loebel, Robert Silva, Robert Goldman, Kei Watabe, Josephine Cucchiaro, Leslie Citrome, John M Kane
OBJECTIVE: To assess the effect of dose increase in adult patients with schizophrenia who demonstrate inadequate initial response to standard-dose lurasidone and to evaluate the efficacy of low-dose lurasidone in adult patients with schizophrenia. METHODS: In this randomized, double-blind, placebo-controlled study conducted between May 2013 and June 2014, hospitalized patients with acute schizophrenia (DSM-IV-TR criteria) were randomly assigned to double-blind treatment with lurasidone 20 mg/d (n = 101), lurasidone 80 mg/d (n = 199), or placebo (n = 112)...
December 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27372312/antipsychotic-drug-induced-somnolence-incidence-mechanisms-and-management
#20
REVIEW
Fang Fang, Hongwei Sun, Zuowei Wang, Ming Ren, Joseph R Calabrese, Keming Gao
Somnolence is a common side effect of antipsychotics. To assess the incidence of this side effect, we performed a MEDLINE search for randomized, double-blinded, placebo- or active-controlled studies of adult patients treated with antipsychotics for schizophrenia, mania, bipolar depression, or bipolar disorder. We extracted rates of somnolence from original publications and pooled them based on the dose of each antipsychotic in the same psychiatric condition, then estimated the absolute risk increase (ARI) and the number needed to harm (NNH) of an antipsychotic relative to placebo or an active comparator in the same psychiatric condition...
September 2016: CNS Drugs
keyword
keyword
27111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"